High impact
The post reports that Parabilis Medicines, a little-known biotech, had a larger IPO pop than SpaceX and that Regeneron is already invested in it.
Finnhub06/28, 07:20 AM
Related assets
Coming up for REGN
Explore next
Latest REGN news
Bloomberg07/31, 06:40 PM
FirstSquawk07/31, 12:37 PM
JPMorgan raised Regeneron Pharmaceuticals price target to $900 from $850.
ZeroHedge07/30, 06:54 PM